United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide   inhalation solution 0.02%   read complete instructions carefully before using. note: use only as directed by your physician.  more frequent administration or higher  doses are not recommended. ipratropium  bromide inhalation solution can be mixed in  the nebulizer with albuterol or metaproterenol  if used within one hour but not with  other drugs. drug stability and safety of  ipratropium bromide inhalation solution  when mixed with other drugs in the nebulizer  have not been established.   store between 59°f (15°c) and 86°f (30°c). protect from l

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide inhalation solution 0.02% read complete instructions carefully before using. note: use only as directed by your physician. more frequent administration or higher doses are not recommended. ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. drug stability and safety of ipratropium bromide inhalation solution when mixed with other drugs in the nebulizer have not been established. store between 59°f (15°c) and 86°f (30°). protect from light. store unused

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

proficient rx lp - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

cobalt laboratories, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium cation - unii:gr88g0i6ul) - solution - 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ipratropium bromide monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ipratropium bromide monohydrate -

Canada - English - Health Canada

pharmascience inc - ipratropium bromide - solution - 125mcg - ipratropium bromide 125mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

pharmascience inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics